Sanara MedTech (Sanara MedTech) ROCE % : 0.16% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Sanara MedTech's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.16%.

Sanara MedTech ROCE % Historical Data

The historical data trend for Sanara MedTech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech ROCE % Chart

Sanara MedTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-60.24

-60.07

-43.61

-35.46

-7.32

Sanara MedTech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-33.14	-9.97	-15.27	-6.56	0.16

Sanara MedTech ROCE % Calculation

Sanara MedTech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3.964	/	( ( (61.035 - 12.806)	+	(73.871 - 13.768) )	/ 2 )
	=	-3.964	/	( (48.229	+	60.103)	/ 2 )
	=	-3.964	/	54.166
	=	-7.32 %

Sanara MedTech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	0.1	/	( ( (75.474 - 13.227)	+	(73.871 - 13.768) )	/ 2 )
	=	0.1	/	( ( 62.247	+	60.103 )	/ 2 )
	=	0.1	/	61.175
	=	0.16 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Sanara MedTech (NAS:SMTI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Sanara MedTech ROCE % Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanara MedTech (Sanara MedTech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102

Website

https://www.sanaramedtech.com

Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.

Executives

Eric D Major	director	751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming	officer: President - Surgical Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman	officer: President - Wound Care Div.	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon	officer: President - R&D	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein	director	5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger	director	1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison	officer: President - Telehealth Svcs.	1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack	director	1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich	10 percent owner	C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena	director, officer: Principal Executive Officer	1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil	officer: Chief Financial Officer	1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc.	10 percent owner	1375 ENCLAVE PARKWAY, HOUSTON TX 77077